17 Sep 2024 update: This is now the first of a 3-part newsletter series! See also part 2 (“R&D Implications: Global Burden of Disease is 28% Infectious!“) and part 3 (17 Sep 2024: “#AMRSOS! AMR could worsen, killing 39m during 2025-2050”). Dear All, There are days when it is hard to keep up! Not only
Dear All (wonkish alert … but definitely worth the effort! Refill your coffee!),Ramanan Laxminarayan and about 40 colleagues from around the world have just published in the Lancet a GLORIOUS collection of papers on the theme of “Sustainable Access to Effective Antibiotics.”There are six papers in total for you to digest: An Executive Summary, four papers with
Dear All, Anthony McDonnell and his colleagues at CGD (Center for Global Development) have just released a truly lovely paper on the economics of antibiotic resistance. What makes this one special is that the paper dissects the problem of AMR through an economist’s spectacles in a way that is very accessible to the non-expert. You
Dear All, This evening I’d like to bring together several relatively recent reports and note how all of them focus in one way or another on Pulling for Pandemic Preparedness … perhaps we can call this the Rule of 3 Ps. And as an aside, I’ll note that I learned the Rule of 4 Ps
Dear All, Four big reports have recently been released and are very much worth reviewing. First, the Global AMR R&D Hub and the WHO AMR Team have written a report entitled “Incentivising the development of new antibacterial treatments“. This report is a response to a 2021 request by the G7 Finance Ministers for a report on
Dear All (and with thanks to Damiano for taking the lead on this newsletter): In advance of Italy assuming the G7 Presidency for 2024, The European House – Ambrosetti (an Italian think tank and management consulting firm) published a new report on 15 November 2023 entitled “Value and sustainability of antibiotics as essential tools for the healthcare
Dear All (and with thanks to Kevin for co-authoring), In a clear and compelling policy paper, a dozen of the DRIVE-AB alumni have proposed a concept for a pan-EU/EEA Pull Incentive. To follow the plot, here are the key points as a refresh: To date, the only strong, active Pull model is the UK NHS project that
Dear All, As we discussed in the 5 Nov 2023 “Pulling for Pandemic Preparedness” newsletter, AMR is a global threat: resistance in one part of the world can suddenly appear in your hospital. As an example of that sort of threat, Jason Gale’s 30 Oct 2023 newsletter entitled “Untreatable Typhoid Should Make You Worry About Poop”
Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), We’ve written before about the UK’s “Netflix” pilot antibiotic Pull incentive in which England leads the way on showing how it plans to provide its fair share of a global antibacterial Pull incentive (for background on Pull incentives, see this superb 5-minute video explainer). In
Dear All (wonkish alert: coffee up, settle in, and read the reports!), As you will recall, WHO’s most current pipeline review found that globally we do not have sufficient innovation as yet to address current or future needs (Butler et al. AAC 2022; see also this newsletter as well as the amr.solutions webpage summarizing pipeline reviews